Am J Perinatol 2014; 31(08): 701-710
DOI: 10.1055/s-0033-1358772
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Re-analysis of Safety Data Supporting Doxylamine Use for Nausea and Vomiting of Pregnancy

Jessica W. S. Chin
1   Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada
,
Sarah Gregor
1   Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada
,
Navindra Persaud
1   Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada
2   Department of Family and Community Medicine, St Michael's Hospital, Toronto, Ontario, Canada
3   Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada
› Author Affiliations
Further Information

Publication History

05 November 2012

23 August 2013

Publication Date:
09 December 2013 (online)

Preview

Abstract

Antihistamines are commonly used to treat nausea and vomiting of pregnancy (NVP). We re-analyzed the 24 primary studies cited in a 1997 meta-analysis that concluded antihistamine use for NVP was safe as they had been studied in more than 200,000 participating women and the pooled odds ratio for congenital malformations was 0.76 (95% confidence interval [CI]: 0.60–0.94). Our analysis of this meta-analysis showed that 139,414 women were included in 22 original studies involving antihistamines, 129,108 of which were in studies involving doxylamine. In these studies, 23,485 women were exposed to antihistamines, 14,624 of which were exposed to doxylamine. The summary relative risk (cohort studies) and odds ratio (case–control studies) for congenital malformations from antihistamine exposure were 1.09 (95% CI: 1.01–1.18) and 1.04 (95% CI: 0.91–1.19), and for doxylamine exposure, the summary relative risk and odds ratio were 0.94 (95% CI: 0.80–1.10) and 1.07 (95% CI: 0.93–1.23), respectively. Although not a new systematic review, our re-analysis demonstrates that the safety data for antihistamines, and doxylamine in particular, are based on many fewer than 200,000 participating women and exposures, and that doxylamine use is not associated with a decreased risk of malformations as previously reported.